PMID- 30082370
OWN - NLM
STAT- MEDLINE
DCOM- 20191024
LR  - 20231115
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 8
IP  - 8
DP  - 2018 Aug 5
TI  - Using routinely collected data to understand and predict adverse outcomes in 
      opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) 
      Study.
PG  - e025204
LID - 10.1136/bmjopen-2018-025204 [doi]
LID - e025204
AB  - INTRODUCTION: North America is amid an opioid use epidemic. Opioid agonist 
      treatment (OAT) effectively reduces extramedical opioid use and related harms. As 
      with all pharmacological treatments, there are risks associated with OAT, 
      including fatal overdose. There is a need to better understand risk for adverse 
      outcomes during and after OAT, and for innovative approaches to identifying 
      people at greatest risk of adverse outcomes. The Opioid Agonist Treatment and 
      Safety study aims to address these questions so as to inform the expansion of OAT 
      in the USA. METHODS AND ANALYSIS: This is a retrospective cohort study using 
      linked, routinely collected health data for all people seeking OAT in New South 
      Wales, Australia, between 2001 and 2017. Linked data include hospitalisation, 
      emergency department presentation, mental health diagnoses, incarceration and 
      mortality. We will use standard regression techniques to model the magnitude and 
      risk factors for adverse outcomes (eg, mortality, unplanned hospitalisation and 
      emergency department presentation, and unplanned treatment cessation) during and 
      after OAT, and machine learning approaches to develop a risk-prediction model. 
      ETHICS AND DISSEMINATION: This study has been approved by the Population and 
      Health Services Research Ethics Committee (2018HRE0205). Results will be reported 
      in accordance with the REporting of studies Conducted using Observational 
      Routinely-collected health Data statement.
CI  - (c) Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Larney, Sarah
AU  - Larney S
AUID- ORCID: 0000-0002-5602-4963
AD  - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 
      New South Wales, Australia.
FAU - Hickman, Matthew
AU  - Hickman M
AD  - Population Health Sciences, Bristol Medical School, University of Bristol, 
      Bristol, UK.
FAU - Fiellin, David A
AU  - Fiellin DA
AD  - Schools of Medicine and Public Health, Yale University, New Haven, Connecticut, 
      USA.
FAU - Dobbins, Timothy
AU  - Dobbins T
AD  - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 
      New South Wales, Australia.
FAU - Nielsen, Suzanne
AU  - Nielsen S
AD  - Monash Addiction Research Centre, Monash University, Melbourne, Victoria, 
      Australia.
FAU - Jones, Nicola R
AU  - Jones NR
AD  - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 
      New South Wales, Australia.
FAU - Mattick, Richard P
AU  - Mattick RP
AD  - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 
      New South Wales, Australia.
FAU - Ali, Robert
AU  - Ali R
AD  - Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
FAU - Degenhardt, Louisa
AU  - Degenhardt L
AD  - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 
      New South Wales, Australia.
LA  - eng
GR  - 12/136/105/DH_/Department of Health/United Kingdom
GR  - MR/K006525/1/MRC_/Medical Research Council/United Kingdom
GR  - R01 DA044170/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180805
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Receptors, Opioid)
RN  - 40D3SCR4GZ (Buprenorphine)
RN  - UC6VBE7V1Z (Methadone)
SB  - IM
MH  - Analgesics, Opioid/*adverse effects
MH  - Buprenorphine/*adverse effects
MH  - Drug Overdose/mortality
MH  - Emergency Service, Hospital/statistics & numerical data
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Methadone/*adverse effects
MH  - New South Wales/epidemiology
MH  - Opioid-Related Disorders/*drug therapy
MH  - Patient Dropouts/statistics & numerical data
MH  - Receptors, Opioid/*agonists
MH  - Regression Analysis
MH  - Research Design
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC6078240
OTO - NOTNLM
OT  - buprenorphine
OT  - data linkage
OT  - methadone
OT  - opiate substitution treatment
COIS- Competing interests: SL has received an untied educational grant from Indivior. 
      LD has received untied educational grants from Indivior, Seqiris, and 
      Mundipharma. MH reports honoraria for speaking at meetings from Gilead, Abbvie 
      and MSD. SN has been an investigator on untied investigator-driven educational 
      grants funded by Indivior and Reckitt-Benckiser, and has had travel costs covered 
      and honoraria paid to her institution to provide training on identification and 
      management of codeine dependence by Indivior.
EDAT- 2018/08/08 06:00
MHDA- 2019/10/28 06:00
PMCR- 2018/08/05
CRDT- 2018/08/08 06:00
PHST- 2018/08/08 06:00 [entrez]
PHST- 2018/08/08 06:00 [pubmed]
PHST- 2019/10/28 06:00 [medline]
PHST- 2018/08/05 00:00 [pmc-release]
AID - bmjopen-2018-025204 [pii]
AID - 10.1136/bmjopen-2018-025204 [doi]
PST - epublish
SO  - BMJ Open. 2018 Aug 5;8(8):e025204. doi: 10.1136/bmjopen-2018-025204.